Brief: Intelgenx Submits Response To Crl From FDA For Rizaport® Versafilm®
18/10/2022 13:10
Intelgenx Technologies Corp IGX.TO :
* INTELGENX SUBMITS RESPONSE TO CRL FROM FDA FOR RIZAPORT®
VERSAFILM®
Source text for Eikon: ID:nGNX9FwC2G
Further company coverage: IGX.TO
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA